AstraZeneca's lung cancer trial drug combination did not meet the main goal.

AstraZeneca said that its experimental drug ceralasertib, in combination with the approved cancer treatment drug Imfinzi, did not meet the primary goal in a late-stage clinical trial for advanced lung cancer. The British pharmaceutical company stated on Monday that the research results showed that the ceralasertib combination did not achieve the overall survival rate compared to standard therapy for patients with locally advanced or metastatic non-small cell lung cancer. AstraZeneca also stated that the combination of ceralasertib and Imfinzi was generally well tolerated, with no new safety concerns.